Minerva Neurosciences Inc (NERV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has a cash flow conversion efficiency ratio of 21.365x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.43 Billion) by net assets ($-254.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Minerva Neurosciences Inc for the company's overall valuation and market capitalisation.
Minerva Neurosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Minerva Neurosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Minerva Neurosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Minerva Neurosciences Inc ranked by their cash flow conversion efficiency. Explore Minerva Neurosciences Inc (NERV) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EGH Acquisition Corp. Class A Ordinary Shares
NASDAQ:EGHA
|
-0.002x |
|
Shuttle Inc
TW:2405
|
0.006x |
|
Webster Financial Corporation
NYSE:WBS
|
0.033x |
|
Asia Tech Image
TWO:4974
|
0.004x |
|
Finward Bancorp
NASDAQ:FNWD
|
0.007x |
|
Invicta
JSE:IVT
|
0.052x |
|
KORE Group Holdings Inc
NYSE:KORE
|
-0.025x |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
4.017x |
Annual Cash Flow Conversion Efficiency for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Minerva Neurosciences Inc from 2012 to 2025. View Minerva Neurosciences Inc (NERV) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-140.75 Million | $-13.51 Billion | 95.994x | +12515.38% |
| 2024-12-31 | $-25.69 Million | $-19.55 Million | 0.761x | +46.46% |
| 2023-12-31 | $-28.46 Million | $-14.78 Million | 0.520x | -57.79% |
| 2022-12-31 | $-20.02 Million | $-24.65 Million | 1.231x | +139.90% |
| 2021-12-31 | $7.98 Million | $-24.60 Million | -3.085x | -380.29% |
| 2020-12-31 | $52.66 Million | $-33.82 Million | -0.642x | +58.92% |
| 2019-12-31 | $27.78 Million | $-43.43 Million | -1.563x | -236.48% |
| 2018-12-31 | $90.26 Million | $-41.94 Million | -0.465x | -2077.04% |
| 2017-12-31 | $131.60 Million | $3.09 Million | 0.024x | +109.70% |
| 2016-12-31 | $105.98 Million | $-25.69 Million | -0.242x | +44.75% |
| 2015-12-31 | $55.32 Million | $-24.27 Million | -0.439x | +37.17% |
| 2014-12-31 | $51.50 Million | $-35.96 Million | -0.698x | -552.28% |
| 2013-12-31 | $20.18 Million | $-2.16 Million | -0.107x | +99.78% |
| 2012-12-31 | $19.02K | $-908.54K | -47.770x | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more